Novartis, Medicines for Malaria Say Treatment for Babies Shows Efficacy
Novartis AG ADR NVS
News
-
Novartis Gets FDA Approval for Lutathera in Pediatric Treatment
Trending: Novartis Shares Climb on Guidance Lift
Novartis Raises Guidance on Profit, Sales Growth — Update
Novartis shares jump as drugmaker boosts outlook
Novartis Raises Guidance on Profit, Sales Growth
Novartis Gets Priority Review for Kidney Disease Treatment
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Trending: Novartis Begins Tender Offer for MorphoSys Shares
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
Novartis Adjusts Manufacturing of Breast Cancer Drug Ribociclib
Novartis Says Early Addition of Cholesterol Drug Shows Positive Results in Trial
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
Novartis Shares Rise After Trial Data Supports New Filing for Cancer Drug
Novartis, Roche's Food Allergies Treatment Xolair Gets FDA Approval
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk
Novartis to bolster its cancer-drug portfolio with $2.9 billion deal for MorphoSys
MorphoSys Shares Jump After It Agrees to $2.9 Billion Takeover by Novartis